2010
Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia
Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 1188-1195. PMID: 21183291, PMCID: PMC3053128, DOI: 10.1016/j.ijrobp.2010.10.007.Peer-Reviewed Original ResearchConceptsTumor cell killingTumor hypoxiaCell killingRadiation fractionation schemesTumor biological effective doseBiological effective doseTumor cell killRegions of hypoxiaRadiotherapy regimenTreatment failureConventional fractionationNeck cancerStandard fractionationProstate cancerTumor cell populationFractionation schemeRadiation therapyTumor clonogensTumor oxygenationBlood vessels resultsCell killEffective doseAlternate fractionationResistant cellsHypoxia
2003
Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives
Chen Z, Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. International Journal Of Radiation Oncology • Biology • Physics 2003, 55: 825-834. PMID: 12573770, DOI: 10.1016/s0360-3016(02)04282-7.Peer-Reviewed Original Research
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds